Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul K. Tomich is active.

Publication


Featured researches published by Paul K. Tomich.


Pharmaceutical Research | 1993

Development of Activity Assays for High-Volume Evaluation of Human Immunodeficiency Virus (HIV) Protease Inhibitors in Rat Serum: Results with Ditekiren

Karen F. Wilkinson; Bob D. Rush; Satish K. Sharma; David B. Evans; Mary J. Ruwart; Janice M. Friis; Michael John Bohanon; Paul K. Tomich

We showed previously that a commercially available synthetic tetradecapeptide, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser, produces authentic angiotensin I (Ang I) upon incubation with the HIV-1 protease (S. K. Sharma et al., Anal. Biochem. 198:363, 1991). Therefore, we developed an Ang-I based activity assay for HIV protease inhibitors based on the technology developed earlier (M. J. Ruwart et al., Pharm. Res. 7:407, 1990; S. K. Sharma et al., Anal. Biochem. 186:24, 1990) for tracking renin inhibitors in rat sera. Ditekiren was either extracted from sera with ethyl acetate or assayed after the interfering substances in sera were precipitated with acetonitrile. Purified recombinant HIV-1 protease was added to extracted rat serum and the enzymatic reaction was initiated in the presence of the tetradecapeptide substrate. The inhibition of Ang I production was measured by a commercially available RIA kit. The cleanup methodology also enabled a commercially available Proteinase Scintillation Proximity Assay (SPA, Amersham) to quantify ditekiren in rat serum through the addition of recombinant HIV-1 protease and cleavage of substrate from SPA beads. Results were confirmed by HPLC or by the renin assay for ditekiren, which inhibits both aspartyl proteases. These technologies should prove useful for assessing serum levels of HIV protease inhibitors in rat.


Genetic engineering | 1990

The Utility of Streptomycetes as Hosts for Gene Cloning

Paul K. Tomich; Yoshihiko Yagi

As in other biological areas, modern scientific techniques such as recombinant DNA methodology have helped to harvest the fruits of knowledge for those species belonging to the genus Streptomyces. This genus has long provided many useful products such as antibacterial and antineoplasia antibiotics (e.g., 1–4), immunomodulators (5) and a variety of enzymes such as proteases (6,7), restriction enzymes (8,9), amylases (10), xylanases (11), and agarases (12). In addition, Streptomyces ssp. deserve study in their own right because they have an interesting life cycle.


Journal of Medicinal Chemistry | 1995

Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.

Suvit Thaisrivongs; Keith D. Watenpaugh; Howe Wj; Paul K. Tomich; Lester A. Dolak; Chong Kt; C.-S. C. Tomich; Alfredo G. Tomasselli; Steven Ronald Turner; Joseph Walter Strohbach; A. M. Mulichak; Musiri N. Janakiraman; Joseph B. Moon; Janet C. Lynn; Miao-Miao Horng; Roger R. Hinshaw; Kimberly A. Curry; D. J. Rothrock


Journal of Medicinal Chemistry | 1996

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

Suvit Thaisrivongs; Harvey I. Skulnick; Steven Ronald Turner; Joseph Walter Strohbach; Ruben A Tommasi; Paul D. Johnson; Paul A. Aristoff; T.M Judge; Ronald B. Gammill; Joel Morris; K.R Romines; R.A Chrusciel; Roger R. Hinshaw; Chong Kt; W.G Tarpley; S.M Poppe; D.E Slade; Janet C. Lynn; Miao-Miao Horng; Paul K. Tomich; Eric P. Seest; Lester A. Dolak; Howe Wj; G.M Howard; Keith D. Watenpaugh


Journal of Medicinal Chemistry | 1997

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.

Harvey I. Skulnick; Paul D. Johnson; Paul A. Aristoff; Morris Jk; Lovasz Kd; Howe Wj; Keith D. Watenpaugh; M.N Janakiraman; D.J Anderson; R.J Reischer; T.M Schwartz; L.S Banitt; Paul K. Tomich; Janet C. Lynn; Miao-Miao Horng; Chong Kt; Roger R. Hinshaw; Lester A. Dolak; Eric P. Seest; Francis J. Schwende; Bob D. Rush; G.M Howard; L.N Toth; K.R Wilkinson; T.J Kakuk; C.W Johnson; S.L Cole; R.M Zaya; G.L Zipp; P.L Possert


Journal of Medicinal Chemistry | 1995

Structure-Based Design of Sulfonamide-Substituted Non-Peptidic HIV Protease Inhibitors

Harvey I. Skulnick; Paul D. Johnson; Howe Wj; Paul K. Tomich; Chong Kt; Keith D. Watenpaugh; Musiri N. Janakiraman; Lester A. Dolak; McGrath Jp; Janet C. Lynn


Journal of Medicinal Chemistry | 1996

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.

Romines Kr; Joel Morris; Howe Wj; Paul K. Tomich; Miao-Miao Horng; Chong Kt; Roger R. Hinshaw; Anderson Dj; Joseph Walter Strohbach; Turner; Mizsak Sa


Archive | 1994

4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections

Paul K. Tomich; Michael John Bohanon; Steven Ronald Turner; Joseph Walter Strohbach; Suvit Thaisrivongs; Richard C. Thomas; Karen Rene Romines; Chih-Ping Yang; Paul A. Aristoff; Harvey I. Skulnick; Paul D. Johnson; Ronald B. Gammill; Qingwei Zhang; Gordon L. Bundy; David John Anderson; Lee S Banitt


Journal of Medicinal Chemistry | 1995

Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure

Romines Kr; Keith D. Watenpaugh; Howe Wj; Paul K. Tomich; Lovasz Kd; Morris Jk; Musiri N. Janakiraman; Janet C. Lynn; Miao-Miao Horng; Chong Kt


Archive | 2001

Methods of identifying compounds that bind to target species under isothermal denaturing conditions

Paul K. Tomich; Dennis E. Epps; Ferenc J. Kezdy; Charles K. Marschke; Ronald W. Sarver

Researchain Logo
Decentralizing Knowledge